Oral amrinone in refractory congestive heart failure.
Publication/Presentation Date
6-1-1980
Abstract
The acute effects of an oral preparation of amrinone, a recently synthesized cardiotonic agent, were assessed noninvasively in nine patients who had advanced heart failure that persisted despite treatment with digitalis, diuretic drugs and afterload-reducing agents. All patients demonstrated an improvement in left ventricular ejection fraction determined by radionuclide ventriculography (20.3 +/- 2.8 to 30.8 +/- 4.8 percent [mean +/- standard error of the mean], p less than 0.005) after a single dose of amrinone. Initial effects were seen within 1 hour, with the peak effect occurring at 1 to 3 hours; persistent effects were demonstrable at 4 to 6 hours. No change in blood pressure, heart rate or rhythm was observed, and there was no clinical evidence of myocardial ischemia. Continued benefit was demonstrated by radionuclide ventriculography in two patients treated for 1 and 6 weeks, respectively, although two other patients experienced major side effects with the chronic administration of amrinone. Although orally administered amrinone shows promise as a potentially useful agent in the treatment of advanced heart failure, the safety of this drug remains to be established.
Volume
45
Issue
6
First Page
1245
Last Page
1249
ISSN
0002-9149
Published In/Presented At
Wynne, J., Malacoff, R. F., Benotti, J. R., Curfman, G. D., Grossman, W., Holman, B. L., Smith, T. W., & Braunwald, E. (1980). Oral amrinone in refractory congestive heart failure. The American journal of cardiology, 45(6), 1245–1249. https://doi.org/10.1016/0002-9149(80)90485-3
Disciplines
Medicine and Health Sciences
PubMedID
7377123
Department(s)
Department of Medicine
Document Type
Article